NCT04256707 · OUTCOME

Monotherapy: Percent Fraction Unbound (fu) of Selinexor (Tablet A) in Plasma Protein

Relative Bioavailability/Bioequivalence of Different Formulations of Selinexor, the Impact of Hepatic Impairment on Selinexor Pharmacokinetics, Tolerability and Antitumor Activity of Selinexor Combination Treatment · Source last updated 2026-10-09

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure: MEAN
Unit: Percent unbound
Interval / dispersion: Standard Deviation
Time frame: At 3 and 8 hours post-dose on Days 1 and 8

What was measured

Fu represents the unbound fraction, which is the portion of the drug in the bloodstream that is unbound to plasma proteins. Mean percent fraction unbound of selinexor (Tablet A) in plasma, calculated by averaging the percent fraction unbound measurements obtained at 3 and 8 hours post-dose on Days 1 and 8.

Analysis population: PK analysis was defined as all participants in the monotherapy part who received at least 1 dose of selinexor and had at least 1 post-dose PK measurement without important protocol deviations/violations or events thought to significantly affect the PK of selinexor (e.g., vomited at or before 6 hours; wrong dose administered; prohibited concomitant medication). Here 'Overall Number of Participants Analyzed' signifies number of participants who were evaluable for this outcome measure.

Groups in this outcome

Monotherapy: Tablet A (Selinexor 5 x 20 mg Tablet): Normal Hepatic Function

Participants with normal hepatic function received Tablet A (selinexor 5 × 20 mg tablets) orally QW on Day 1 or Day 8, until PD, intolerability, or Investigator decision.

Monotherapy: Tablet A (Selinexor 2 × 20 mg Tablet): Moderate Hepatic Function

Participants with moderate hepatic function received Tablet A (selinexor 2 × 20 mg tablets) orally QW on Day 1 until PD, intolerability, or Investigator decision.

Monotherapy: Tablet A (Selinexor 2 x 20 mg Tablet) Severe Hepatic Function

Participants with severe hepatic function received Tablet A (selinexor 2 × 20 mg tablets) orally QW on Day 1 until PD, intolerability, or Investigator decision.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

Group	Source count
Monotherapy: Tablet A (Selinexor 5 x 20 mg Tablet): Normal Hepatic Function	12
Monotherapy: Tablet A (Selinexor 2 × 20 mg Tablet): Moderate Hepatic Function	7
Monotherapy: Tablet A (Selinexor 2 x 20 mg Tablet) Severe Hepatic Function	6

Reported measurements

Source class 1

Values in Percent unbound · Interval/dispersion: Standard Deviation
Group	Value	Spread	Lower	Upper	Comment
Monotherapy: Tablet A (Selinexor 5 x 20 mg Tablet): Normal Hepatic Function	4.19	0.918	Not reported	Not reported	Not reported
Monotherapy: Tablet A (Selinexor 2 × 20 mg Tablet): Moderate Hepatic Function	5.33	1.11	Not reported	Not reported	Not reported
Monotherapy: Tablet A (Selinexor 2 x 20 mg Tablet) Severe Hepatic Function	4.4	0.505	Not reported	Not reported	Not reported

Complete source fields

classes

categories
measurements
group Id
OG000
spread
0.918
value
4.19
group Id
OG001
spread
1.11
value
5.33
group Id
OG002
spread
0.505
value
4.4

denoms

counts
group Id
OG000
value
12
group Id
OG001
value
7
group Id
OG002
value
6
units
Participants

description

dispersion Type

Standard Deviation

groups

description
Participants with normal hepatic function received Tablet A (selinexor 5 × 20 mg tablets) orally QW on Day 1 or Day 8, until PD, intolerability, or Investigator decision.
id
OG000
title
Monotherapy: Tablet A (Selinexor 5 x 20 mg Tablet): Normal Hepatic Function
description
Participants with moderate hepatic function received Tablet A (selinexor 2 × 20 mg tablets) orally QW on Day 1 until PD, intolerability, or Investigator decision.
id
OG001
title
Monotherapy: Tablet A (Selinexor 2 × 20 mg Tablet): Moderate Hepatic Function
description
Participants with severe hepatic function received Tablet A (selinexor 2 × 20 mg tablets) orally QW on Day 1 until PD, intolerability, or Investigator decision.
id
OG002
title
Monotherapy: Tablet A (Selinexor 2 x 20 mg Tablet) Severe Hepatic Function

param Type

MEAN

population Description

PK analysis was defined as all participants in the monotherapy part who received at least 1 dose of selinexor and had at least 1 post-dose PK measurement without important protocol deviations/violations or events thought to significantly affect the PK of selinexor (e.g., vomited at or before 6 hours; wrong dose administered; prohibited concomitant medication). Here 'Overall Number of Participants Analyzed' signifies number of participants who were evaluable for this outcome measure.

reporting Status

POSTED

time Frame

At 3 and 8 hours post-dose on Days 1 and 8

title

Monotherapy: Percent Fraction Unbound (fu) of Selinexor (Tablet A) in Plasma Protein

type

SECONDARY

unit Of Measure

Percent unbound

Download exact source JSON → · Snapshot ctgov-results-d643ffaf417bcef6d45eb5e0

Preserved source evidence · Not medical advice